Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Michallet, Anne-Sophie, Aktan, Melih, Hiddemann, Wolfgang, Ilhan, Osman, Johansson, Peter, Laribi, Kamel, Meddeb, Balkis, Moreno, Carol, Raposo, João, Schuh, Anna, Ünal, Ali, Widenius, Tom, Bernhardt, Alf, Kellershohn, Kerstin, Messeri, Dimitri, Osborne, Stuart, Leblond, Véronique
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865431/
https://ncbi.nlm.nih.gov/pubmed/29419437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.170480
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados